Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clariane SECHIX:CLARIP 60 EV-to-EBITDA is 7.53 as of Jul. 21, 2026, which is 29% below its 10-year median of 10.65. GuruFocus rates CHIX:CLARIP with a GF Score™ of 60/100 and a GF Value™ of €2.47 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 506 Healthcare Providers & Services companies, Clariane SE ranks better than 70.16% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Clariane SE's enterprise value is €8,688 Mil.
Clariane SE's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €1,153 Mil. Therefore, Clariane SE's EV-to-EBITDA for today is 7.53.
The historical rank and industry rank for Clariane SE's EV-to-EBITDA or its related term are showing as below:
CHIX:CLARIp'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.36 Med: 10.65 Max: 14.62
Current: 7.53
During the past 13 years, the highest EV-to-EBITDA of Clariane SE was 14.62. The lowest was 7.36. And the median was 10.65.
CHIX:CLARIp's EV-to-EBITDA is ranked better than 70.16% of 506
companies
in the Healthcare Providers & Services industry
Industry Median: 11.075
vs CHIX:CLARIp: 7.53
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Clariane SE (CHIX:CLARIp) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Clariane SE's PE Ratio (TTM) for today is calculated as:
Clariane SE's share price for today is €4.126.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clariane SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Clariane SE's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CLARIP vs HCA, THC, DVA: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Clariane SE's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clariane SE EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Clariane SE's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Clariane SE's EV-to-EBITDA falls into.
Clariane SE's current Enterprise Value is €8,688 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clariane SE's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €1,153 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clariane SE (CHIX:CLARIP) has a EV-to-EBITDA of 7.53 as of Jul. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Clariane SE. This is 29% below median its historical median of 10.65. Over the past decade, Clariane SE's EV-to-EBITDA has ranged from 7.36 to 14.62. According to the industry distribution chart, Clariane SE ranks #151 out of 506 companies in the Healthcare Providers & Services industry, placing it in the top 29.8%.
Is Clariane SE's EV-to-EBITDA too high?
Clariane SE's current EV-to-EBITDA of 7.53 is 29% below median its 10-year median of 10.65. Over the past 10 years, this metric has ranged from a low of 7.36 to a high of 14.62. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.08. Clariane SE's value of 7.53 is 32% below this industry median. Based on the distribution chart, Clariane SE ranks #151 out of 506 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Clariane SE has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Clariane SE ranks #151 out of 506 companies for EV-to-EBITDA. This puts Clariane SE in the upper half of its industry. The industry median EV-to-EBITDA is 11.08. Clariane SE's value of 7.53 is 32% below this benchmark. Historically, Clariane SE's own EV-to-EBITDA has ranged from 7.36 to 14.62 over the past decade. While the company's 10-year median is 10.65 vs. the industry median of 11.08, Clariane SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.08, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clariane SE's current EV-to-EBITDA of 7.53 is 32% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Clariane SE. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clariane SE's current EV-to-EBITDA is 7.53, which is 29% below median its own 10-year median of 10.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (CHIX:CLARIP) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.47, compared to a current price of €4.13 — trading 67% above its estimated fair value. The current EV-to-EBITDA is 7.53, which is 29% below median its 10-year median of 10.65 and 32% below the Healthcare Providers & Services industry median of 11.08. Clariane SE's overall GF Score™ is 60/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Clariane SE (CHIX:CLARIP), the current EV-to-EBITDA is 7.53 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clariane SE (CHIX:CLARIP) Overvalued in 2026?
Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued.
The current stock price of €4.13 is trading 67% above its estimated GF Value™ of €2.47.
GuruFocus considers Clariane SE to be Significantly Overvalued.
Key valuation signals for CHIX:CLARIP:
EV-to-EBITDA: 7.53 (29% below median its 10-year median of 10.65)
GF Value™: €2.47 vs. price of €4.13 (67% above fair value)
Industry Position: 32% below the Healthcare Providers & Services median (#151 of 506)
No single metric tells the full story. See the CHIX:CLARIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
60GF Score
Get the complete analysis for CHIX:CLARIP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CLARIP has been successfully added to your 
